Overview

Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study intends to evaluate how safe and well tolerated the LY2405319 compound is when given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also determine if there is a positive effect on lowering the level of glucose in people with type 2 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company